It falls on teams that prepared properly but still lost.
CureVac had worked on mRNA since 2000. It ran a 40,000-person trial and held a European order for up to 405 million doses. In mid-2021, its vaccine's final efficacy came in at 48%, against about 95% for rivals using the same technology.
The preparation put CureVac in the race. It could not decide the result.
In 1988, Jonathan Baron and John Hershey named this trap outcome bias: people rated the same medical decision worse when told the patient had died. A 2023 replication with 692 participants found the same effect. In drug development, only 7.9% of candidates entering Phase I between 2011 and 2020 reached approval, so even excellent programs usually fail.
Outcomes still carry information. Ten lost tenders in a row say something about the bids.
Public tenders invite the same mistake. A team submits a compliant dossier, prices carefully, meets every deadline, and loses by a margin it couldn't see. The next bid gets half the preparation.
Before the award is announced:
- Score what the team controlled: compliance, documents, lead times, price logic.
- List what it could not control, such as a rival's price or a budget change.
- Hold the preparation standard, whatever this award decides.
When you lost your last tender, did the review judge the bid or the award?
